Eli Lilly and Company (LLY)
Stock Price Chart
Key Info
| Market Cap | 146.27B |
| Revenue (ttm) | 22.95B |
| Net Income (ttm) | 5.62B |
| Shares Out | 956.47M |
| EPS (ttm) | 6.15 |
| PE Ratio | 24.87 |
| Forward PE | 22.42 |
| Dividend | $2.96 |
| Dividend Yield | 1.94% |
Stock Quote
| Trading Day | Aug 7, 2020 |
| Last Price | $152.93 |
| Previous Close | $152.88 |
| Change ($) | 0.05 |
| Change (%) | 0.03% |
| Day's Open | 152.89 |
| Day's Range | 151.58 - 153.50 |
| Day's Volume | 2,017,370 |
| 52-Week Range | 101.36 - 170.75 |
More Stats
| Market Cap | 146.27B |
| Enterprise Value | 160.21B |
| Earnings Date (est) | Oct 27, 2020 |
| Ex-Dividend Date | May 14, 2020 |
| Shares Outstanding | 956.47M |
| Float | 793.68M |
| EPS (basic) | 6.19 |
| EPS (diluted) | 6.15 |
| FCF / Share | 5.76 |
| Dividend | $2.96 |
| Dividend Yield | 1.94% |
| Earnings Yield | 4.02% |
| FCF Yield | 3.57% |
| Payout Ratio | 44.70% |
| Shares Short | 5.23M |
| Short Ratio | 1.39 |
| Short % of Float | 0.66% |
| Beta | 0.22 |
| PE Ratio | 24.87 |
| Forward PE | 22.42 |
| P/FCF Ratio | 28.01 |
| PS Ratio | 6.37 |
| PB Ratio | 35.73 |
| Revenue | 22.95B |
| Operating Income | 6.39B |
| Net Income | 5.62B |
| Free Cash Flow | 5.22B |
| Net Cash | -13.94B |
| Net Cash / Share | -14.57 |
| Gross Margin | 76.68% |
| Operating Margin | 27.85% |
| Profit Margin | 24.50% |
| FCF Margin | 22.75% |
| ROA | 9.90% |
| ROE | 157.61% |
| ROIC | 20.30% |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 22,320 | 21,493 | 19,974 | 21,222 | 19,959 | 19,616 | 23,113 | 22,603 | 24,287 | 23,076 |
| Revenue Growth | 3.84% | 7.61% | -5.88% | 6.33% | 1.75% | -15.13% | 2.25% | -6.93% | 5.25% | - |
| Gross Profit | 17,598 | 16,812 | 15,526 | 15,512 | 14,922 | 14,683 | 18,205 | 17,807 | 19,219 | 18,710 |
| Operating Income | 5,266 | 3,680 | 2,305 | 3,374 | 2,790 | 3,000 | 5,889 | 5,408 | 5,350 | 6,525 |
| Net Income | 8,318 | 3,232 | -204 | 2,738 | 2,408 | 2,391 | 4,685 | 4,089 | 4,348 | 5,070 |
| Shares Outstanding | 931 | 1,028 | 1,052 | 1,058 | 1,062 | 1,070 | 1,081 | 1,113 | 1,158 | 1,153 |
| Earnings Per Share | 8.89 | 3.13 | -0.19 | 2.58 | 2.26 | 2.23 | 4.32 | 3.66 | 3.90 | 4.58 |
| EPS Growth | 184.03% | - | - | 14.16% | 1.35% | -48.38% | 18.03% | -6.15% | -14.85% | - |
| Dividend Per Share | 2.58 | 2.25 | 2.08 | 2.04 | 2.00 | 1.96 | 1.96 | 1.96 | 1.96 | 1.96 |
| Dividend Growth | 14.62% | 8.22% | 1.96% | 2% | 2.04% | 0% | 0% | 0% | 0% | - |
| Operating Cash Flow | 4,837 | 5,525 | 5,616 | 4,851 | 2,965 | 4,458 | 5,735 | 5,305 | 7,235 | 6,857 |
| Capital Expenditures | -1,034 | -1,211 | -1,077 | -964 | -974 | -1,147 | -833 | -883 | -647 | -670 |
| Free Cash Flow | 3,803 | 4,314 | 4,539 | 3,887 | 1,991 | 3,311 | 4,902 | 4,421 | 6,588 | 6,187 |
| Cash & Equivalents | 2,439 | 7,409 | 8,034 | 6,039 | 4,452 | 10,233 | 5,397 | 5,684 | 6,897 | 6,727 |
| Total Debt | 15,317 | 10,299 | 13,647 | 10,305 | 7,979 | 8,022 | 5,213 | 5,531 | 6,987 | 6,927 |
| Net Cash / Debt | -12,879 | -2,890 | -5,613 | -4,267 | -3,527 | 2,211 | 184 | 153 | -89.90 | -200 |
| Assets | 39,286 | 43,908 | 44,981 | 38,806 | 35,569 | 36,308 | 35,249 | 34,399 | 33,660 | 31,001 |
| Liabilities | 36,587 | 32,999 | 33,313 | 24,725 | 20,979 | 20,920 | 17,608 | 19,625 | 20,124 | 18,589 |
| Book Value | 2,607 | 9,829 | 11,592 | 14,008 | 14,571 | 15,373 | 17,631 | 14,765 | 13,536 | 12,413 |
Company Profile
Company Details
| Full Name | Eli Lilly and Company |
| Country | United States |
| Employees | 34,720 |
| CEO | David A. Ricks |
Stock Information
| Ticker Symbol | LLY |
| Stock Exchange | New York Stock Exchange |
| Sector | Healthcare |
| Industry | Drug Manufacturers—General |
| Unique Identifier | NYSE: LLY |
Description
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It offers endocrinology products for diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and paediatric growth conditions. The company also provides neuroscience products for treating depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; migraine and episodic cluster headache; attention-deficit hyperactivity disorder; and schizophrenia. In addition, it offers immunology products for the treatment of rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis; oncology products to treat non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and products to treat erectile dysfunction and benign prostatic hyperplasia. Eli Lilly and Company primarily has collaborations with Incyte Corporation; Pfizer Inc.; Dicerna Pharmaceuticals, Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; Duke Clinical Research Institute for the prevention of chronic heart failure and mortality after an acute myocardial infarction; AbCellera Biologics Inc.; and Sermonix Pharmaceuticals Inc., as well as an agreement with Junshi Biosciences to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.